Many aromatase inhibitors (AIs) were developed for the treatment of breast cancer, such as aminoglutethimide (AG), the first AI used in clinic and was ultimately withdrew due to its high toxicity and low selectivity [6]. Here, CYP19A1 is linked to breast carcinoma.